BioRestorative Therapies (STU:9OF) Forward Dividend Yield %: 0.00% (As of Jul. 01, 2026)


STU:9OF BioRestorative Therapies Inc STU:9OF
60 GF Score
Price €0.32
GF Value €1.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Forward Dividend Yield %?

BioRestorative Therapies STU:9OF -1.25% 60 Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus rates STU:9OF with a GF Score™ of 60/100 and a GF Value™ of €1.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 147 Biotechnology companies, BioRestorative Therapies ranks worse than 680271.43% on this metric.

As of today (2026-07-01), the Forward Annual Dividend Yield of BioRestorative Therapies is 0.00%.

As of today (2026-07-01), the Trailing Annual Dividend Yield of BioRestorative Therapies is 0.00%.

STU:9OF's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

BioRestorative Therapies's Dividends per Share for the three months ended in Mar. 2026 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


BioRestorative Therapies  (STU:9OF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


BioRestorative Therapies Forward Dividend Yield % Related Terms


STU:9OF vs CVKD, JSPR, APRE: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Forward Dividend Yield % falls into.


STU:9OF
60GF Score
BioRestorative Therapies Inc STU:9OF
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
BioRestorative Therapies (STU:9OF) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #999999 out of 147 companies in the Biotechnology industry.
Is BioRestorative Therapies' Forward Dividend Yield % too high?
BioRestorative Therapies' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, BioRestorative Therapies ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Forward Dividend Yield % compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #999999 out of 147 companies for Forward Dividend Yield %. This places BioRestorative Therapies in the lower half of its industry. The industry median Forward Dividend Yield % is 1.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.45, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (STU:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.27, compared to a current price of €0.32 — trading 75.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. BioRestorative Therapies' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For BioRestorative Therapies (STU:9OF), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (STU:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.32 is trading 75.1% below its estimated GF Value™ of €1.27. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for STU:9OF:

  • Forward Dividend Yield %: 0.00%
  • GF Value™: €1.27 vs. price of €0.32 (75.1% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the STU:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioRestorative Therapies Business Description

Other Exchanges BRTX:USA9OF:Germany
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
60GF Score

Get the complete analysis for STU:9OF

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€1.27
GF Value